- Conditions
- Pelvic Organ Prolapse, Gynecologic Cancers, Uterine Leiomyomata, Adenomyosis, Endometrial Hyperplasia, Other Abnormal Uterine and Vaginal Bleeding, Pelvic Mass, Pelvic Pain
- Interventions
- Not listed
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- Tampa, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–35
of 35
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Endometrial Hyperplasia
- Interventions
- Ultrasound and Biopsy
- Procedure
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 45 Years to 75 Years · Female only
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Endometrial Hyperplasia
- Interventions
- BAY865028, Medroxyprogesterone acetate
- Combination Product · Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • West Hills, California + 19 more
- Conditions
- Atypical Endometrial Hyperplasia, Endometrial Carcinoma
- Interventions
- Megestrol Acetate, Pterostilbene
- Drug · Biological
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Endometrial Atypical Hyperplasia, Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, Endometrial Cancer Stage I, Endometrial Cancer, Fertility-Sparing Treatment (FST), Obesity & Overweight
- Interventions
- Semaglutide (Wegovy) weekly injection, LNG-IUD (Progestin), Structured Weight Loss Program
- Drug · Device · Behavioral
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2031
- U.S. locations
- 4
- States / cities
- Houston, Texas
- Conditions
- Endometrial Endometrioid Adenocarcinoma, Endometrial Hyperplasia
- Interventions
- Biopsy Procedure, Curettage Procedure, Hysterectomy, Megestrol Acetate, Progesterone Only Hormone Replacement Therapy
- Procedure · Drug
- Lead sponsor
- New Mexico Cancer Research Alliance
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 4
- States / cities
- Iowa City, Iowa • Albuquerque, New Mexico • Salt Lake City, Utah + 1 more
- Conditions
- Post Operative Pain, Gynecologic Cancer
- Interventions
- Liposomal bupivacaine, Bupivacain
- Drug
- Lead sponsor
- Tufts Medical Center
- Other
- Eligibility
- 18 Years to 80 Years · Female only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Complex Atypical Hyperplasia, Endometrial Cancer
- Interventions
- Metformin
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 2
- States / cities
- Chapel Hill, North Carolina • Cincinnati, Ohio
- Conditions
- Grade 1 Endometrial Endometrioid Adenocarcinoma, Grade 2 Endometrial Endometrioid Adenocarcinoma, Complex Atypical Endometrial Hyperplasia
- Interventions
- Depot medroxyprogesterone acetate, Placebo
- Drug · Other
- Lead sponsor
- Women and Infants Hospital of Rhode Island
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Lynch Syndrome, Endometrial Cancer, Endometrial Hyperplasia, Mismatch Repair Deficiency, Microsatellite Instability
- Interventions
- Immunohistochemical staining
- Diagnostic Test
- Lead sponsor
- WellSpan Health
- Other
- Eligibility
- 18 Years to 99 Years · Female only
- Enrollment
- 91 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- York, Pennsylvania
- Conditions
- Atypical Hyperplasia, Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, Endometrial Carcinoma, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
- Interventions
- Exemestane, Laboratory Biomarker Analysis, Pharmacokinetic Study, Questionnaire Administration
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 45 Years and older · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Minneapolis, Minnesota • Madison, Wisconsin